AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05319275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg (2×250 mg/tablet) after meal, 3 times per day
Trial: NCT00301834
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02617537
Drug: EE20/DRSP(YAZ,BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
Trial: NCT02617537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets for 28 days per 28-day intake cycle
Trial: NCT04100642
Drug: Hemay808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical apply
Trial: NCT04100642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical apply
Trial: NCT00368160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT00637923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
Trial: NCT00601965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill of daily oral escitalopram
Trial: NCT03634514
Drug: Recombinant human growth hormone - Hormotrop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
Trial: NCT01890161
Drug: AXP1275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXP1275 50 mg (2 × 25-mg capsules)
Trial: NCT01890161
Drug: AXP1275 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXP1275 matching placebo (2 capsules)
Trial: NCT01893437
Drug: RO6799477
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of RO6799477
Trial: NCT02292667
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
Trial: NCT01202214
Drug: 1440115
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01202214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01839487
Drug: PEGPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
Trial: NCT00190567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03019796
Drug: MEDICATION AND EXERCISE TRAINING
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE).
Trial: NCT00436033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03427411
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
Trial: NCT01516593
Drug: Induction Phase
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * dd -2 to 1: Methylprednisolone~* dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~* dd 2, Rituximab~* dd 7, Methotrexate~* dd 14, Rituximab~* dd 15, Etoposide~* dd 21, Methotrexate~* dd 29, Rituximab and Doxorubicin~* dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~1. pts in CR: consolidation phase followed by bulky site irradiation~2. pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~3. pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation
Trial: NCT01516593
Drug: Consolidation Phase (on day +50)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * dd 1-2: cytarabine twice a day~* dd 3 and 11: rituximab~* dd 11-13: leukapheresis for PBPC collection.
Trial: NCT03212365
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 40 mg enoxaparin twice daily
Trial: NCT04394624
Drug: SAR408701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion
Trial: NCT00461565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Trial: NCT00461565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Trial: NCT01155999
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
Trial: NCT00409773
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
Trial: NCT00409773
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks.
Trial: NCT00049231
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03697460
Drug: INCB018424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.
Trial: NCT03170713
Drug: arveles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Trial: NCT03170713
Drug: intrafen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Trial: NCT01398241
Drug: RO5267683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses
Trial: NCT01398241
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses
Trial: NCT01938417
Drug: tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03773055
Drug: NPC-06
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive once a day for 7 days.
Trial: NCT04058613
Drug: ALB Protein, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
Trial: NCT04123392
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT00515320
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily oral dispersible tablet 2mg 9mg or 18mg
Trial: NCT00117377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo application bid
Trial: NCT00515320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dispersible tablet placebo
Trial: NCT05787028
Drug: AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one AD16 tablet in the morning
Trial: NCT05787028
Drug: AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take a placebo pill matching AD16 once in the morning
Trial: NCT00321113
Drug: steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03408899
Drug: PC-1005 gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
Trial: NCT01525953
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy according to standard
Trial: NCT04319705
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
Trial: NCT04319705
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
Trial: NCT00312442
Drug: Treatment with WST09 Vascular Photodynamic therapy
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03023501
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02359968
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiochemotherapy before surgery
Trial: NCT02961842
Drug: Intrathecal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 15 µg will be administered in the subarachnoid space
Trial: NCT02961842
Drug: 500 mL Crystalloid Coload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
Trial: NCT02961842
Drug: 1000 mL Crystalloid Coload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
Trial: NCT04642989
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate standard-of-care antibiotics as determined by the physician.
Trial: NCT03563222
Drug: Intralipid, 20%
RxNorm normalized name: Intralipid, 20% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy.
Trial: NCT03736967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC q2w
Trial: NCT01490411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
Trial: NCT00879190
Drug: Ampicillin/gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
Trial: NCT01939054
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01539304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dry syrup, b.i.d
Trial: NCT02634346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing
Trial: NCT00605644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00802425
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intratympanic injection
Trial: NCT04446533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).
Trial: NCT02573220
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02573220
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01458587
Drug: Aminolevulinic Acid PDT (ALA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Trial: NCT00932256
Drug: STAHIST NDC #58407-536-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
Trial: NCT02052362
Drug: ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-450, ABT-267 and ritonavir
Trial: NCT02453607
Drug: thiopurine
RxNorm normalized name: Thiopurine methyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
Trial: NCT00977197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be administered twice a day
Trial: NCT03758469
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Trial: NCT03248037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops
Trial: NCT02650817
Drug: RAD1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD1901, a novel selective ER degrader (SERD)
Trial: NCT00784693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV single dose
Trial: NCT02968810
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01944423
Drug: Pill Placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02897349
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02897349
Drug: background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insulin with or without metformin
Trial: NCT00083915
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m2 continuous infusion days -3 and -2.
Trial: NCT00586560
Drug: Kareniticin and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity.
Trial: NCT02873234
Drug: Antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
Trial: NCT01235988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + standard of care
Trial: NCT04771637
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
Trial: NCT01362257
Drug: Treatment Period 1 - IV dose of GSK573719
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 65µg
Trial: NCT03086213
Drug: Sulfentanyl
RxNorm normalized name: Sufentanyl
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anaesthetic
Trial: NCT01932554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
Trial: NCT01932554
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Scheduled ibuprofen,\~10 mg/kg every 6-8 hours
Trial: NCT04011618
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
Trial: NCT03794167
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
Trial: NCT03226236
Drug: High-Dose IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
Trial: NCT03117036
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with curative intent
Trial: NCT00731042
Drug: Avagard
RxNorm normalized name: Avagard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution, 6 mL, 6 applications/day for 14 days.
Trial: NCT01482611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
Trial: NCT01482611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
Trial: NCT01482611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
Trial: NCT01482611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
Trial: NCT01939912
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic agent.
Trial: NCT03265782
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days